ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,582.00 ▲ 21.20 (1.36%)ENR.DE: $160.76 ▼ -1.74 (-1.07%)GLEN.L: $533.90 ▼ -1.40 (-0.26%)IFX.DE: $81.67 ▲ 1.11 (1.38%)NOKIA.HE: $12.38 ▲ 0.38 (3.17%)RIO.L: $7,261.00 ▼ -3.00 (-0.04%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

XBiotech Inc.

XBIT - NASDAQ

Identifiants & Marche

Ticker XBIT
ISIN CA98400H1029
CIK 0001626878
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.